Health & Biotech
Check out the latest Drug Development news, insights and unique analysis brought to you by Stockhead's team of business journalists and industry experts.
Health & Biotech
Health Check: ASX ‘Magnificent Seven’ rides high amidst the US healthcare mayhem
Health & Biotech
Emerging ASX healthcare innovators are ready to impress at HealthInvest 2025
StockTake
StockTake: Another country under the belt
Health & Biotech
Health Check: LTR Pharma finds fast-track path to US erectile dysfunction market
Health & Biotech
Biocurious: When it comes to accurate measuring, the sky’s not the limit for Trajan
Health & Biotech
Health Check: Bargain hunters flock to 4D Medical’s discounted raising
Health & Biotech
Health Check: Opthea’s solvency in question after monumental phase III eye disease trial failure
Long Shortz
Long Shortz with Neurizon Therapeutics: Clinical hold lift on the horizon
Health & Biotech
Health Check: Emvision’s stroke detector takes to the skies
Health & Biotech
Biocurious: FDA approval remains the Holy Grail for ASX life science stocks
Health & Biotech
Health Check: Fantastico! Telix wins Brazilian assent for prostate cancer imaging agent
Health & Biotech
Health Check: These biotechs are awaiting key announcements on St Patrick’s Day
Health & Biotech
Race gets ethics nod for Phase I trial in solid tumour patients
Health & Biotech
Health Check: All hail the hard-working bodily ‘spuds’ – it’s World Kidney Day
Health & Biotech
Botanix climbs into ASX 300 club, strengthening its global dermatology ambitions
Health & Biotech
Biocurious: For Recce, our near neighbour was the obvious place to launch a diabetes-related trial
Health & Biotech
Health Check: Poly oh no! Polynovo shares resume slide as CEO goes
Health & Biotech
Health Check: More healthcare ‘reverse ferrets’ from Trump’s razor gang
Health & Biotech
Race inks key contract to advance trial of cardioprotective anticancer treatment
Health & Biotech
Health Check: Telix ‘mini me’ Clarity moves to next phase of prostate cancer therapy trial
Biocurious: Sometimes an effective therapy lies not just with the drug, but how it is delivered
Health & Biotech
Dimerix banks initial $3.2m payment in Japanese pharma licensing deal for kidney drug
Health & Biotech
Health Check: Half-price sale as brokers ring the bell on Neuren shares
Health & Biotech
Health Check: More biotechs change their names, but will they smell just as sweet?
Health & Biotech
ReNerve inks Mexican deal for nerve repair product NervAlign
Health & Biotech
Health Check: You’re rehired! The Trump administration’s FDA staffing ‘fiasco’ puts sector in choppy, unchartered waters
Health & Biotech
Health Check: What’s up, Doc? Not much – post Covid patients are still avoiding GP visits
Health & Biotech
Biocurious: With Mayne Pharmaceuticals under takeover offer, who’s next?
Health & Biotech
Health Check: More, please! When record results are not good enough for expectant investors
Health & Biotech
Health Check: After an ‘extraordinary’ year, analysts reckon Telix has a lot more tiger in the tank
Health & Biotech
Health Check: It’s show-and-tell time for three of our home-grown heroes
Health & Biotech
Health Check: EBOS Group’s earnings surge – or plunge – but bottom line is, pharmacies are in rude health
Health & Biotech
Biocurious: Cashed up and pursuing the ‘c’ word, Imugene is on the verge of transforming cancer immunotherapy
Health & Biotech
Health Check: With its last patient treated, Opthea eyes pending results of do-or-die trial
Health & Biotech
Health Check: Brokers slash Cochlear valuations as customers hold tight on product upgrades
Health & Biotech
Health Check: Despite a ‘biggest ever’ December half, Pro Medicus says it’s just revving up in the US
Health & Biotech
Island completes dosing in phase 2b arm of mosquito-borne dengue trial
Health & Biotech
Health Check: Vitura Health swoops on medical dope telehealth platform
Health & Biotech
Biocurious: Hut Hut Hut! The growing list of ASX biotechs waiting for the FDA to call the start of play
Health & Biotech
Health Check: CSL’s blood business saves the day amid declining flu jab rates
Health & Biotech
Health Check: Percheron ‘closes the book’ on failed childhood rare disease program
Health & Biotech
Biocurious: Consumer health minnow Wellnex Life gears up for company-making Eurotrip
Health & Biotech
Health Check: Ahead of Chemist Warehouse merger, brokers ring bell on ‘overvalued’ Sigma shares
Health & Biotech
Health Check: Good golly Miss Molly! Emyria says Ecstasy works for PTSD, months after treatment
Health & Biotech
Paradigm eyes $110m plus raise with shareholder loyalty offer
Health & Biotech
Paradigm closer to phase III clinical trial with appointment of preferred CRO
Health & Biotech
Health Check: Fisher & Paykel Healthcare shares tumble after Trump tariff king-hit
Load More